New Research Finds Markers to Predict Omalizumab Responses

This article originally appeared here.
Baseline periostin level, free IgE during treatment follow-up tied to asthma exacerbations
Baseline periostin level, free IgE during treatment follow-up tied to asthma exacerbations

HealthDay News — Baseline serum periostin levels and levels of serum free immunoglobulin E (IgE) during treatment follow-up may be useful in assessing response to omalizumab treatment for asthma, according to a study published online April 26 in Allergy.

Tomoko Tajiri, from Kyoto University in Japan, and colleagues assessed the utility of biomarkers of type 2 inflammation (free serum IgE levels) in predicting omalizumab treatment responses. Response was defined as the absence of asthma exacerbation during the first year of treatment. The study included 30 patients who were treated with omalizumab for at least 1 year, with 27 of them treated for 2 years. 

Related Articles

The researchers found that patients without exacerbations during the first year of treatment had significantly higher baseline serum periostin levels and blood eosinophil counts than patients with exacerbations. There was a negative association between baseline serum periostin levels, but not eosinophil counts, and free serum IgE levels after 16 or 32 weeks of treatment. Reduced exacerbation numbers at two years were seen in those with reduced free serum IgE levels during treatment. For the 14 patients who had exacerbations during the first year of treatment, exacerbation numbers gradually and significantly decreased over the two-year study period, with simultaneous significant reductions in free serum IgE levels.

"Baseline serum periostin levels and serum free IgE levels during treatment follow-up may be useful in evaluating responses to omalizumab treatment," conclude the authors.

Several authors report financial ties to the pharmaceutical industry. One author disclosed a patent application for serum periostin for treatment of bronchial asthma.

Abstract
Full Text (subscription or payment may be required)

Loading links....